Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 16/20 | 0.52 |
| ▸ | GIPR | P48546 | 6/20 | 0.52 |
| ▸ | GLP1R | P43220 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666398 | 0.94 | GCGR (0.48) | GCGRGIPRGLP1RFABP4CYP3A4 | |
| SCHEMBL2653677 | 0.91 | GCGR (0.53) | GCGRGIPRGLP1RFABP4CYP3A4 | |
| SCHEMBL2654563 | 0.90 | GCGR (0.56) | GCGRGIPRGLP1RCYP3A4CYP2C8 | |
| SCHEMBL4086785 | 0.89 | GCGR (0.59) | GCGRGIPRGLP1R | |
| SCHEMBL2660359 | 0.88 | GCGR (0.61) | GCGRGIPRGLP1RCYP3A4CYP2C8 | |
| SCHEMBL2663153 | 0.85 | GCGR (0.60) | GCGRGIPRGLP1R | |
| SCHEMBL2659728 | 0.79 | GCGR (0.51) | GCGRGIPRGLP1R | |
| SCHEMBL2666415 | 0.78 | GCGR (0.48) | GCGRGIPRGLP1R | |
| SCHEMBL2654548 | 0.77 | GCGR (0.68) | GCGRGIPRGLP1RCYP3A4CYP2C8 | |
| SCHEMBL2654975 | 0.77 | GCGR (0.49) | GCGRGIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.